Month: 2025-10

Oct 27, 2025 - (ACN Newswire via SeaPRwire.com) - The International Leo Tolstoy Peace Prize Jury announced the 2025 laureates in recognition of outstanding efforts contributing to regional harmony and security in Central Asia. The award honors the signing of the Treaty on the Junction Point of State Borders and the Khujand Declaration of Eternal Friendship in Khujand, Tajikistan, on March 31, 2025 — landmark agreements that strengthen legal frameworks for mutual trust and cross-border collaboration.Established on June 22, 2022, by the Russian Historical Society, the Russian Peace Foundation, and the Russian Military Historical Society, the International Leo Tolstoy Peace Prize Foundation convenes juries including prominent figures from Argentina, Belarus, India, China, Russia, France, South Africa, and Japan. Jury Chairman Valery Gergiev, renowned conductor and artistic director of the Mariinsky Theatre, emphasized the prize’s mission to “advance global understanding and mutual respect.” He noted the growing reach of the peace movement inspired by Russian writer-philosopher Leo Tolstoy, expressing hope that the prize could, like music, “help nations listen and truly hear one another.”The 2025 honor celebrates the joint efforts of:- Sadyr Japarov, Kyrgyz Republic- Emomali Rahmon, Republic of Tajikistan- Shavkat Mirziyoyev, Republic of UzbekistanTheir collaboration has strengthened stability, sustainable growth, and the international profile of Central Asia. The award ceremony date will be announced soon.About the PrizeThe International Leo Tolstoy Peace Prize is awarded by an international jury established by the founders of the L.N. Tolstoy International Peace Prize Foundation. The jury is composed of distinguished Russian and foreign figures of recognized international standing and moral authority.Candidates for the Prize may include individuals, initiative groups, national and international public foundations, organizations, movements, scientific and research centers, as well as educational institutions. Self-nomination is not permitted; however, nominators are encouraged to publicly discuss the candidates they propose. Rooted in the humanist ideals of Leo Tolstoy, the Prize honors those whose work embodies the pursuit of peace, moral integrity, and shared progress for humanity.Media contactOrganization: The International Leo Tolstoy Peace PrizeContact: Media teamWebsite: https://tolstoypeaceprize.org Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, Oct 27, 2025 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 27 October 2025, the Group through its subsidiary CMS VISION INTERNATIONAL MANAGEMENT LIMITED entered into a Distribution Agreement (the “Agreement”) with Novartis Pharma Services AG (“Novartis”) for Ranibizumab Injection (“Lucentis®”) and Brolucizumab Injection (“Beovu®”). In accordance with the Agreement, the Group has obtained the exclusive right to import, distribute, sell and promote as specifically agreed upon in the Agreement in the People’s Republic of China (for the purpose of the Agreement, excluding the Hong Kong Special Administrative Region, the Macao Special Administrative Region and Taiwan) ; Novartis will continue to be responsible for the production and supply of the products. The term of cooperation comes into effect on the effective date of the Agreement and remains valid for a period of five years.Both collaborative products have been approved for marketing in China. Among them, Lucentis® is the first anti-vascular endothelial growth factor (VEGF) drug approved for ophthalmic use in China, and has accumulated mature clinical application experience, providing reliable support for numerous patients with ocular fundus diseases. Lucentis® has been approved for the treatment of multiple ocular neovascular diseases, including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), macular edema following retinal vein occlusion (RVO), etc. Another product, Beovu®, is a next-generation anti-VEGF drug approved in China in May 2025 for the treatment of DME. Leveraging its innovative advantages of ultra-small molecular weight (only 26 kDa) and high concentration, Beovu® significantly improves retinal anatomical structure, helps more DME patients gain visual improvement, and alleviates treatment burden.The Group’s ophthalmology business company, “CMS Vision”, focuses on deploying and developing innovative ophthalmic pharmaceuticals and medical devices with urgent clinical needs on a global scale, striving to become a “leading ophthalmology pharmaceutical company in China”. This collaboration will enhance the overall competitiveness of CMS Vision in the field of ophthalmology. CMS Vision already covers ophthalmic disease areas such as fundus diseases, asthenopia and glaucoma. With the addition of Lucentis® and Beovu®, the portfolio will generate strong synergies with the marketed exclusive drug Augentropfen Stulln Mono Eye Drops (Esculin and Digitalisglycosides Eye Drops) and the marketed exclusive medical device EyeOP1 Glaucoma Treatment Device in terms of customer base, expert resources, and channel networks. This will further strengthen CMS Vision’s academic brand competitiveness in ophthalmology, provide positive momentum for sustained collaboration and the development of clinically needed innovative ophthalmic products, and offer patients more diverse treatment options. At the same time, CMS Vision’s professional ophthalmology team will integrate marketing channels and academic resources to improve the overall team efficiency. The collaboration is expected to have a positive impact on the Group’s financial results.More Information about LUCENTIS® and Ocular Neovascular DiseasesLucentis® is a recombinant humanized monoclonal antibody Fab fragment targeting VEGF. It targets and inhibits human vascular endothelial growth factor A (VEGF-A), thereby suppressing vascular endothelial cell proliferation, neovascularization, and vascular leakage. As the first anti-VEGF drug approved for ophthalmic use in China[3], Lucentis® has been approved for the treatment of multiple ocular neovascular diseases since its launch in China in 2011, including nAMD, DME, macular edema following RVO, choroidal neovascularization (CNV), diabetic retinopathy (DR), and retinopathy of prematurity (ROP). In 2017, Lucentis® was included in the National Reimbursement Drug List (NRDL) for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance. It has accumulated mature clinical application experience, providing reliable support for numerous patients with ocular fundus diseases.Ocular neovascular diseases are a group of severe blinding ophthalmic conditions characterized by increased vascular permeability, vascular leakage, and loss of vascular integrity, mainly including nAMD, DR, DME, RVO, CNV, ROP, etc. Anti-VEGF drugs are recommended as first-line therapy for ocular neovascular diseases in multiple authoritative guidelines[3, 4]. According to a Frost & Sullivan report, the number of patients with ocular neovascular diseases in China is projected to increase from 47.8 million in 2019 to 61.2 million in 2030. The Chinese ophthalmic anti-VEGF drug market is expected to grow from RMB 2.4 billion in 2019 to RMB 18.6 billion in 2030. As stated in Anti-VEGF Drugs for Fundus Neovascular Diseases, Lucentis®—the first anti-VEGF drug approved for the treatment of ocular neovascular diseases in China—has demonstrated favorable safety and efficacy in multiple clinical trials. It has been widely used in the treatment of ocular neovascular diseases, and its launch represents a major advancement in clinical ophthalmic treatment[5].More Information about BEOVU® and the DME IndicationBeovu® is a novel VEGF-A-targeted humanized single-chain antibody fragment. It received approval from the National Medical Products Administration of China (NMPA) in May 2025 for the treatment of DME. As the current anti-VEGF drug with the smallest molecular weight (only 26 kDa), Beovu® is administered once every 6 weeks during the loading phase of the DME treatment (compared to once every 4 weeks for other anti-VEGF drugs) and once every two to three months during the maintenance phase. In the global Phase 3 KESTREL and KITE Studies for treatment-naive DME patients, Beovu® met all primary efficacy endpoints and the visual benefit persisted until Week 100. Additionally, patients in the Beovu® 6mg group had less intraretinal fluid (IRF) and/or subretinal fluid (SRF). The median number of injections of Beovu® in the first year (7 times) was lower than that of aflibercept (9 times), while its overall safety profile was comparable to the latter[6]. Data from the Chinese real-world study (BEST Study) showed that for previously treated and inadequately controlled DME patients, BCVA improved by 6.1 letters from baseline 1 week after the first injection of Beovu®, and by 10 letters after the third injection (Week 12). Beovu® provides a more optimized treatment option for previously treated DME patients[7].DME is a retinal thickening caused by capillary leakage in the macular area, which is the result of the breakdown of the blood retinal barrier and mainly affects central vision.[8]. According to a Frost & Sullivan report, there are approximately 7.89 million DME patients in China in 2025. However, even with the current standard anti-VEGF regimens, approximately 30%-50% of DME patients still exhibit suboptimal fluid control[9-11]. A survey in the 2022 White Paper on the Current Status of Chronic Disease Management for Common Ocular Fundus Diseases in China showed that treatment adherence among Chinese patients is relatively poor, with over 30% of DME patients failing to complete the loading phase treatment. There is an urgent clinical need for more potent, longer-lasting, and more adherence-friendly treatment options to improve the diagnosis and treatment of DME patients. As a next-generation anti-VEGF drug, Beovu® offers a potential solution to this challenge. Leveraging its innovative advantages of ultra-small molecular weight and high concentration, Beovu® significantly improves retinal anatomical structure, helps more DME patients gain visual improvement, and alleviates treatment burden.About NOVARTISNovartis is a globally renowned pharmaceutical company headquartered in Basel, Switzerland. The company focuses on four core therapeutic areas with urgent patient needs—Cardiovascular, Renal and Metabolic Disease, Oncology, Immunology, and Neuroscience—as well as five key technology platforms: Chemotherapy, Biotherapy, xRNA, Radioligand Therapy, and Gene and Cell Therapy.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference:1. Product-related information can be found on the Novartis website at:https://www.novartis.com.cn/news/big-news-noxtex-welcomes-the-approval-of-dual-indications 2. Lim, Jennifer I et al. “Diabetic Retinopathy Preferred Practice Pattern®.” Ophthalmology vol. 132,4 (2025): P75-P162. doi:10.1016/j.ophtha.2024.12.0203. Chinese Vitreo-Retina Society of Chinese Medical Association, Fundus Disease Group of Chinese Ophthalmologist Association. Evidence-based guidelines for diagnosis and treatment of age-related macular degeneration in China(2023)[J]. Chinese Journal of Ophthalmology,2023,59(5):347-366. 4. Xu Xun, Wang Jianying. Changes in Disease Spectrum Drive the Evolution of Clinical Medications [N]. Health News, 2023-07-05(005).5. Hou Huimin, et al. Anti-VEGF drugs for fundus neovascular diseases[J].International Review of Ophthalmology,2024,48(6):464-470.6. Wykoff CC, Garweg JG, Regillo C, et al. KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular Edema. Am J Ophthalmol. 2024;260:70-83.7. Honghua Yu, 2025 China Forum on Fundus Diseases & International Retina Symposium, June 4-7, Wuxi, China.8. Chinese Vitreo-Retina Society of Chinese Medical Association, Fundus Disease Group of Chinese Ophthalmologist Association. Evidence-based guidelines for diagnosis and treatment of diabetic retinopathy in China (2022)[J]. Chinese Journal of Ocular Fundus Diseases,2023,39(2):99-124.9. Dai Hong, et al. Advances in the treatment strategies of diabetic macular edema and the problems[J]. Chinese Journal of Ocular Fundus Diseases,2022, 38(1): 6-9.10. Bressler, Neil M et al. “Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.” JAMA ophthalmology vol. 136,3 (2018): 257-269.11. Chatziralli, I et al. “Identification of time point to best define 'sub-optimal response' following intravitreal ranibizumab therapy for diabetic macular edema based on real-life data.” Eye (London, England) vol. 31,11 (2017): 1594-1599.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

馬薩諸塞州特克斯伯里, 2025年10月27日 - (亞太商訊 via SeaPRwire.com) - CIL 的全球製造網絡遍佈北美、歐洲與亞洲，使公司能為製藥合作夥伴提供多元且具韌性的供應鏈。每一項 ISOAPI-D 產品皆於通過 ISO 9001 認證的設施中製造，確保在整個生產流程中達到最高的品質標準、法規遵循與完整的可追溯性。ISOAPI-DISOAPI-D Power of Deuterium: Smarter, Stronger TherapeuticsISOAPI-D 系列的核心組成之一為重水（D₂O），該原料僅由經核准的供應商提供。此產品具完整追溯性且不含氚（tritium），符合製藥產業嚴格的安全與法規要求。ISOAPI-D 系列同樣包含先進的中間體，可使合成途徑更加簡化。透過減少合成步驟並優化生產效率，這些中間體有助於降低製造成本，並加速新療法的上市進程。自 1981 年以來，CIL 一直是全球領先製藥與生物技術公司的優質去氘材料可信賴供應商。隨著 ISOAPI-D 的推出，CIL 將這份對品質與可靠性的長期承諾持續延伸，為客戶提供安全、高品質的關鍵試劑供應，並在研發流程中降低營運風險。CIL 去氘試劑應用業務開發經理 Tasha Agreste 表示：「ISOAPI-D 代表了我們持續推動製藥創新的下一步。我們擴展的製造能力、嚴謹的品質標準，以及數十年的專業經驗，使 CIL 成為能滿足業界不斷演變需求的可靠夥伴。」請於 10 月 28 日至 30 日蒞臨法蘭克福國際製藥原料展（CPhI Frankfurt）CIL 展位 #2.0G2，探索 ISOAPI-D —— 去氘化學推動製藥創新的未來。關於Cambridge Isotope Laboratories, Inc.CIL 為日本大塚製藥旗下子公司，是全球最大之穩定同位素及其標記化合物的製造商與供應商。自 1980 年以來，CIL 一直深受業界與學術界合作夥伴信賴，其產品廣泛應用於科研、診斷、環境監測、製藥、醫學檢測、OLED 與工業領域。CIL 的營運據點包括美國麻薩諸塞州波士頓地區的兩座設施、位於俄亥俄州錫尼亞（Xenia, OH）的大型同位素濃縮生產廠，以及 CIL 中國、CIL 加拿大、位於德國德勒斯登的 ABX（專門從事放射性同位素標記化合物，用於癌症診斷與治療），以及位於法國薩克雷（Saclay）的 Eurisotop。聯絡資訊Crissy Kriskocrissyk@isotope.com1.978.269.1930來源: Cambridge Isotope Laboratories, Inc. Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TEWKSBURY, MA, Oct 27, 2025 - (ACN Newswire via SeaPRwire.com) - Cambridge Isotope Laboratories, Inc. (CIL), a global leader in stable isotope chemistry, announces the launch of ISOAPI-D™, a unified brand of deuterated intermediates for API synthesis. The new ISOAPI-D brand will be launched at CPhI Frankfurt, where CIL welcomes industry professionals to stand #2.0G2 from October 28-30.ISOAPI-DISOAPI-D Power of Deuterium: Smarter, Stronger Therapeutics"ISOAPI-D reagents are designed to support the development of next-generation active pharmaceutical ingredients (APIs) by leveraging the unique benefits of deuterium incorporation," said Cliff Caldwell, CEO of CIL. "With ISOAPI-D, our customers gain access to a trusted and secure supply chain, ensuring they have consistent, reliable access to the materials they need for robust and efficient drug development."CIL's global manufacturing network, including facilities in North America, Europe, and Asia, enables CIL to provide a diversified and resilient supply chain for pharmaceutical partners. Every ISOAPI-D product is manufactured in ISO 9001-certified facilities, ensuring the highest standards of quality, regulatory compliance, and full traceability throughout the production process.A core component of the ISOAPI-D line is heavy water (D₂O), which is sourced exclusively from approved suppliers. This product is fully traceable and tritium-free, aligning with stringent safety and regulatory requirements of the pharmaceutical industry.The ISOAPI-D range also features advanced intermediates that allow for more streamlined synthetic pathways. By reducing the number of synthesis steps and optimizing production efficiency, these intermediates can help lower manufacturing costs and accelerate the time to market for new therapeutics.Since 1981, CIL has been a trusted supplier of premium deuterated materials to leading pharmaceutical and biotechnology companies worldwide. This longstanding commitment to quality and reliability continues with the launch of ISOAPI-D, offering customers a secure, high-quality supply of essential reagents and reducing operational risk in their development pipelines."ISOAPI-D represents the next step in our ongoing mission to support pharmaceutical innovation," said Tasha Agreste, Business Development Manager Deuterated Reagent Applications, at CIL. "Our expanded manufacturing capabilities, rigorous quality standards, and decades of experience position CIL as a reliable partner for the industry's evolving needs."Visit CIL at CPhI Frankfurt, Stand #2.0G2, October 28-30, to discover ISOAPI-D, the future of deuterated chemistry for pharmaceuticals.About Cambridge Isotope Laboratories, Inc.CIL, a subsidiary of Otsuka Pharmaceutical in Japan, is the largest manufacturer and global supplier in the world of stable isotopes and stable isotope‑labeled compounds.Trusted by industrial and academic collaborators since 1980, CIL's products are used in research, diagnostics, environmental, pharmaceutical, medical diagnostic, OLED, and industrial applications. CIL's operations include two facilities in the Boston, MA, area; a large isotope‑enrichment production plant in Xenia, OH; CIL China; CIL Canada; ABX in Dresden, Germany (specializing in radioisotopic‑labeled compounds for cancer diagnosis and treatment); and Eurisotop in Saclay, France.Contact InformationCrissy Kriskocrissyk@isotope.com1.978.269.1930SOURCE: Cambridge Isotope Laboratories, Inc. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

麻薩諸塞州特克斯伯里與印度海德拉巴, 2025年10月27日 - (亞太商訊 via SeaPRwire.com) - Cambridge Isotope Laboratories, Inc.，(簡稱 CIL) 與手性與特種化學解決方案領導企業 Chemtatva Chiral Solutions 私人有限公司（Chemtatva Chiral Solutions, Pvt. Ltd.，簡稱 CCS）宣布已簽署諒解備忘錄，共同在印度海得拉巴（Hyderabad）成立Cambridge Isotope Laboratories, Pvt. Ltd.。此項舉措標誌著 CIL 全球版圖擴張的重要里程碑，並進一步強化其在去氘試劑及其他同位素富集產品開發與生產方面的能力。此合作將強化全球供應鏈韌性，為亞洲客戶提供即時支援，並實現多地點生產，確保全球客戶的業務持續運作。預計新實體 Cambridge Isotope Laboratories, Pvt. Ltd.將於 2025 年第 4 季正式成立，具體時程取決於常規盡職調查與交割流程。新公司的初期運營將在 CCS 現有設施中展開，並計劃於 2026 年啟動新廠建設。新設施將座落於印度海得拉巴郊區、佔地 2,000 英畝、快速成長的生命科學園區—— 基因谷（Genome Valley）。CIL 執行長 Cliff Caldwell 表示：「我們非常高興能與 CCS 攜手合作，結合雙方的化學專業，共同推進擴量技術的應用，以進一步支援製藥與工業領域的發展。這一舉措充分體現了我們對全球科研與研發工作的承諾，同時滿足製藥與電子產業對去氘標記與特種化學產品日益增長的商業需求。」CCS 執行長 Vishal Rajput 表示：「此次合作與新成立的公司將充分發揮 CCS 在印度強大的基礎設施與深厚的技術實力，同時結合 CIL 在同位素化學、品質系統、全球物流及市場推廣等方面的世界級標準。」Rajput 先生將擔任新成立之 Cambridge Isotope Laboratories, Pvt. Ltd. 的總經理。原有的 CCS 業務將保持獨立運作，雙方的共同目標是擴大全球客戶對高品質同位素標記及非標記化合物的獲取，特別聚焦於下游合成化合物的應用，並堅守各產業特定的產品品質要求。CIL、Eurisotop 與 CCS 所有品牌及製造的產品仍將透過現有渠道供應印度及全球客戶。關於 Cambridge Isotope Labs Pvt. Ltd. 的正式啟動及營運範圍，更多細節將於未來數月內公布。關於Cambridge Isotope Laboratories, Inc.CIL 為日本大塚製藥旗下子公司，是全球最大之穩定同位素及其標記化合物的製造商與供應商。自 1980 年以來，CIL 一直深受業界與學術界合作夥伴信賴，其產品廣泛應用於科研、診斷、環境監測、製藥、醫學檢測、OLED 與工業領域。CIL 的營運據點包括美國麻薩諸塞州波士頓地區的兩座設施、位於俄亥俄州錫尼亞（Xenia, OH）的大型同位素濃縮生產廠，以及 CIL 中國、CIL 加拿大、位於德國德勒斯登的 ABX（專門從事放射性同位素標記化合物，用於癌症診斷與治療），以及位於法國薩克雷（Saclay）的 Eurisotop。關於Chemtatva Chiral Solutions, Pvt. Ltd.CCS 成立於 2021 年，總部位於印度海得拉巴（Hyderabad），專精於手性化學、製程開發與客製化合成，服務對象涵蓋製藥及化學產業。作為生命科學領域值得信賴的全球合作夥伴，CCS 致力於提供創新的化學解決方案，以解決複雜挑戰並加速科學進步。聯絡資訊Crissy Kriskocrissyk@isotope.com1.978.269.1930來源: Cambridge Isotope Laboratories, Inc. Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TEWKSBURY, MA AND HYDERABAD, INDIA, Oct 27, 2025 - (ACN Newswire via SeaPRwire.com) - Cambridge Isotope Laboratories, Inc. (CIL), and Chemtatva Chiral Solutions, Pvt. Ltd. (CCS), a leading provider of chiral and specialty chemical solutions, announce the execution of a signed Memorandum of Understanding to establish Cambridge Isotope Laboratories, Pvt. Ltd. in Hyderabad, India. This initiative marks a milestone in the expansion of CIL's global footprint and further enhances capabilities in the development and production of deuterated reagents and other isotopically enriched products. This partnership will enhance global supply chain strength and real-time support for customers in Asia and enable multi-site production for global customers focused on business continuity. The forthcoming entity, Cambridge Isotope Laboratories, Pvt. Ltd., is expected to be officially established in Q4 2025, subject to customary diligence and closing considerations. Operations for the newly formed entity will be initiated at existing CCS facilities, with a net new facility slated for groundbreaking in 2026. The new facility will be located in India's Genome Valley, a burgeoning 2,000-acre life sciences cluster located in suburban Hyderabad.Cliff Caldwell, CEO at CIL noted, "We are excited to partner with CCS to combine our chemistry expertise and pursue scale-up technologies to further support pharmaceutical and industrial applications. This initiative reflects our commitment to supporting global research and development efforts in scientific fields as well as supporting the growing commercial needs for deuterium labeled and specialty chemical products in the pharmaceutical and electronics industries."Vishal Rajput, CEO of CCS said, "The collaboration and newly formed entity will leverage CCS's strong infrastructure and deep technical capabilities in India, while integrating CIL's world-class standards in isotope chemistry, quality systems, global logistics and go-to market capabilities." Mr. Rajput will lead the newly formed entity as general manager of Cambridge Isotope Laboratories, Pvt. Ltd. The legacy CCS business will remain intact, with the collective intent to expand access to high quality, isotopically labeled and unlabeled compounds for customers worldwide, with an emphasis on downstream synthetic compounds and a commitment to industry-specific product quality requirements.All CIL, Eurisotop and CCS branded and manufactured materials remain available to Indian and worldwide customers through existing channels. Further details regarding the launch and operational scope of Cambridge Isotope Labs Pvt. Ltd. will be shared in the coming months.About Cambridge Isotope Laboratories, Inc.CIL, a subsidiary of Otsuka Pharmaceutical in Japan, is the largest manufacturer and global supplier in the world of stable isotopes and stable isotope‑labeled compounds. Trusted by industrial and academic collaborators since 1980, CIL's products are used in research, diagnostics, environmental, pharmaceutical, medical diagnostic, OLED, and industrial applications. CIL's operations include two facilities in the Boston, MA, area; a large isotope‑enrichment production plant in Xenia, OH; CIL China; CIL Canada; ABX in Dresden, Germany (specializing in radioisotopic‑labeled compounds for cancer diagnosis and treatment); and Eurisotop in Saclay, France.About Chemtatva Chiral Solutions, Pvt. Ltd.CCS is a Hyderabad-based company founded in 2021, specializing in chiral chemistry, process development, and custom synthesis for pharmaceutical and chemical industries. CCS is a trusted global partner in life sciences, delivering innovative chemistry solutions that solve complex challenges and accelerate scientific progress.Contact InformationCrissy Kriskocrissyk@isotope.com1.978.269.1930SOURCE: Cambridge Isotope Laboratories, Inc. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年10月27日 - (亞太商訊 via SeaPRwire.com) - 周大福人壽今日宣佈，與港怡醫院、香港中文大學醫院（「中大醫院」）及香港浸信會醫院（「浸會醫院」）簽署合作備忘錄，建立策略性合作夥伴關係。周大福人壽更成為首間保險公司與港怡醫院其位於金鐘之日間醫療中心合作推出專屬計劃，為客戶提供健康管理方案。同時，「尚逸醫生網絡」全面升級，三家醫院及其附屬醫療中心正式加入，組成更強大的醫療網絡，覆蓋全港，為客戶提供優先轉介、預約及直接結算服務。周大福人壽執行董事兼行政總裁葉文傑表示：「我們非常高興與三家具領導地位的卓越醫院建立長遠合作關係，透過周大福集團生態圈的優勢，為客戶提供更靈活和優質的醫療服務方案，成為他們的人生規劃師 。是次合作不僅進一步鞏固我們全港的醫療網絡，同時亦進一步提升了周大福人壽的服務質量，讓客戶在不同人生階段，能享有更自主、便捷和全面的醫療服務體驗。我們堅信，醫療保障不應止於理賠，應延伸至預防、診斷、治療及康復的每一個階段，真正實踐開創健康新價值。」三區醫療網絡佈局 實現全港覆蓋三家醫院將分別成為周大福人壽於港島、九龍、新界區的指定醫療網絡，醫院醫生及心理健康治療師亦會加入「尚逸醫生網絡」，為客戶提供便捷、優質和全面的醫療服務。港島區：港怡醫院港怡醫院是港島區的指定醫療網絡。為進一步擴展服務範疇，周大福人壽更成為首間保險公司與港怡醫院位於金鐘、新開幕之港怡日間醫療中心合作，推出涵蓋「腸胃鏡檢查」及「疣切除」的專屬計劃，為客戶提供以預防為本的健康管理方案。新界區：中大醫院中大醫院將成為新界區的指定醫療網絡。中大醫院擁有由中大醫學院教授及專科醫生組成的頂尖醫護團隊，再配合其先進的醫療設施與科研實力，為客戶提供涵蓋多個專科的高端醫療服務。醫院致力將國際前沿醫研成果轉化為臨床服務，為客戶帶來世界級的診療體驗，惠及社會大眾。九龍區：浸會醫院浸會醫院將成為九龍區的指定醫療網絡。浸會醫院採用「一院多點」的營運模式，讓客戶能夠就近獲得所需醫療服務。其中，位於觀塘商貿區（牛頭角）的浸信會東九龍醫療中心（EKMC）提供白內障手術及腫瘤科預先批核直付服務; 其心理健康治療師團隊亦會為客戶提供身心靈全方位的照顧，秉持著「全人醫治．榮神益人」的精神。客戶專屬醫療服務 體現以人為本精神透過是次合作，三家醫院將為周大福人壽客戶提供以下服務：- 優先轉介及預約安排，大幅縮短輪候時間- 直接結算服務，客戶無需預先墊支醫療費用，減輕財務壓力- 一站式癌症治療服務，涵蓋診斷、治療、及術後康復，全程支援照顧- 高端醫療對接，為尊貴客戶安排教授級醫生及先進醫療設施，確保最優質的醫療照顧周大福人壽執行董事兼行政總裁葉文傑 (中) 、周大福人壽執行董事兼副行政總裁暨首席財務官徐志堅(右二) 、IHH醫療 (北亞洲) 區域首席執行官兼港怡醫院執行總裁曾慶亷醫生(左二)、香港中文大學醫院行政總裁鍾健禮醫生(右一) 以及香港浸信會醫院行政總監梁誌邦醫生(左一) 出席啟動禮，宣佈周大福人壽與三大醫院建立策略性合作夥伴關係。關於周大福人壽周大福人壽保險有限公司（「周大福人壽」）扎根香港40年，為周大福創建有限公司（「周大福創建」）（香港股份代號：659）的全資附屬公司，也是香港最具規模的壽險公司之一。作為周大福企業成員，周大福人壽緊扣鄭氏家族（「周大福集團」或「集團」）生態圈的雄厚資源，致力為客戶及其摯愛於「生活、成長、健康、傳承」的人生旅程中，提供個人化的匠心規劃、終身保障及優質體驗。憑藉集團財務實力及環球投資佈局，周大福人壽矢志成為亞太區領先的保險公司，持續開創保險新價值。傳媒聯絡周大福人壽企業傳訊部柳麗鳳+852 2591 8297vecinia.lau@ctflife.com.hk周大福人壽保險有限公司（於百慕達註冊成立之有限公司） Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Oct 27, 2025 - (ACN Newswire via SeaPRwire.com) – CTF Life today announced the signing of a Memorandum of Understanding with Gleneagles Hospital Hong Kong (“Gleneagles”), CUHK Medical Centre (“CUHKMC”), and Hong Kong Baptist Hospital (“HKBH”) to establish strategic partnerships. In a pioneering move, CTF Life has also become the first insurance company to collaborate with Gleneagles MediCentre in Admiralty to launch an exclusive programme to provide customers with health management solutions. At the same time, the PrimeChamp Doctor Network has been enhanced with the official inclusion of the three hospitals and their affiliated medical centres. This expanded medical network now spans across Hong Kong, offering customers priority referrals, appointment scheduling and direct billing services.Man Kit Ip, Executive Director and Chief Executive Officer of CTF Life, said, “We are pleased to forge long-term business partnerships with three leading and distinguished hospitals. Harnessing the strengths of the Chow Tai Fook Group ecosystem, we are committed to providing our customers with more flexible and superior medical service solutions, serving as their Life Planner. This collaboration not only further solidifies our medical network across Hong Kong, but also elevates the overall service experience at CTF Life, empowering customers with greater autonomy, convenience and comprehensive medical service experiences at every stage of their life journey. We firmly believe that medical protection should go beyond claims, it should accompany our customers across every stage from prevention and diagnosis to treatment and recovery, truly bringing to life our vision of creating value beyond healthcare.”Territory-wide Medical Network Coverage Across Hong KongThe three hospitals will respectively serve as CTF Life’s designated medical network partners on Hong Kong Island, Kowloon, and the New Territories. Their doctors and mental health therapists will also join the PrimeChamp Doctor Network, providing customers with convenient, high-quality, and comprehensive medical services.Hong Kong Island: Gleneagles Hospital Hong KongGleneagles serves as the appointed medical network partner for Hong Kong Island. CTF Life has also become the first insurance company to collaborate with the newly opened Gleneagles MediCentre in Admiralty, further expanding its service scope through exclusive programmes. These programmes include gastroscopy, colonoscopy and wart removal services, providing customers with prevention-oriented health management solutions.New Territories: CUHK Medical CentreCUHKMC will serve as the selected medical network partner for the New Territories. Backed by a top-tier medical team comprising professors from the CUHK Faculty of Medicine and specialists, coupled with advanced medical facilities and strong research capabilities, CUHKMC provides customers with premium, multi-specialty medical services. Dedicated to translating cutting-edge international medical research into clinical practice, CUHKMC delivers a world-class diagnostic and treatment experience that benefits both customers and the wider community.Kowloon: Hong Kong Baptist HospitalHKBH will serve as the designated medical network partner for Kowloon. Operating under a “One Hospital, Multiple Service Sites” synergy model, the hospital enables patients to conveniently access medical services close to their preferred location. Among these sites, the HKBH East Kowloon Medical Centre (EKMC), located in the Kwun Tong Business District (Ngau Tau Kok), provides pre-approved direct billing services for cataract surgery and oncology treatments. Additionally, mental health team offers professional guidance to help individuals better understand and manage their psychological well-being. Together, these services embrace the Hospital mission: “In the Service of Man, for the Glory of God.”Customer-Exclusive Medical Services Reflects a People-Centric ApproachThrough this collaboration, the three hospitals will offer the following services for CTF Life customers:- Priority referral and appointment scheduling, significantly reducing waiting time.- Direct billing services, allowing customers to receive treatment without upfront payment, easing financial pressure.- One-stop cancer treatment services, covering diagnosis, treatment, and post-surgery rehabilitation, providing comprehensive support throughout the care journey.- Access to premium medical services and coordination, arranging professor-level doctors and advanced medical facilities to ensure customers receive the highest quality of medical care.Man Kit Ip, Executive Director and Chief Executive Officer of CTF Life (middle); Ellick Tsui, Executive Director, Deputy Chief Executive Officer and Chief Financial Officer of CTF Life (second from right); Dr Kenneth Tsang, Regional Chief Executive Officer of IHH Healthcare North Asia and Chief Executive Officer of Gleneagles Hospital Hong Kong (second from left); Dr Chung Kin Lai, Chief Executive Officer of CUHK Medical Centre (first from right); and Dr Leung Chi Bon, Chief Executive Officer of Hong Kong Baptist Hospital (first from left), announce the establishment of strategic partnerships at the kick-off ceremony.About CTF LifeChow Tai Fook Life Insurance Company Limited (“CTF Life”) is proud of its rich, 40-year legacy in Hong Kong. CTF Life is a wholly-owned subsidiary of CTF Services Limited (“CTFS”) (Hong Kong Stock Code: 659) and one of the most well-established life insurance companies in Hong Kong. As a member of Chow Tai Fook Enterprises Limited, CTF Life consistently strengthens its collaboration with the Chow Tai Fook Group ecosystem to support customers and their loved ones in navigating life’s journey with personalised planning solutions, lifelong protection and diverse lifestyle experiences. By leveraging the Group’s robust financial strength and strategic investments across the globe, CTF Life aspires to become a leading insurance company in Asia while continuously creating value beyond insurance.Media enquiriesCTF LifeCorporate Communications DepartmentVecinia Lau+852 2591 8297vecinia.lau@ctflife.com.hk Chow Tai Fook Life Insurance Company Limited (Incorporated in Bermuda with limited liability) Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

- The 27th Hong Kong International Lighting Fair (Autumn Edition) opened today and will run for four days, and the 10th Hong Kong International Outdoor and Tech Light Expo will open tomorrow. The twin lighting fairs bring together some 3,000 exhibitors from 20 countries and regions.- The returning Innovative Lighting Design Forum held today features case studies and global market insights.- Renowned lighting designer Tino Kwan will host a masterclass tomorrow (28 October) at HKCEC titled “The Language of Light: From Artistic Design to Everyday Experience.”- Several exhibitors set up immersive experience zones, to enable visitors to explore product trends in human-centric lighting, artificial intelligence, and the silver market.HONG KONG, Oct 27, 2025 - (ACN Newswire via SeaPRwire.com) – The 27th Hong Kong International Lighting Fair (Autumn Edition), organised by the Hong Kong Trade Development Council (HKTDC), opened today and will run for four days until 30 October at the Hong Kong Convention and Exhibition Centre, while the 10th Hong Kong International Outdoor and Tech Light Expo will take place from 28 to 31 October at AsiaWorld-Expo.Deputy Executive Director of the HKTDC Jenny Koo said: "The development of innovative lighting products is thriving, with significant growth potential. Under the theme “Illuminated Designs for a Smarter Future”, the twin lighting fairs showcase innovative products and smart lighting solutions from some 3,000 exhibitors across 20 countries and regions. The fairs are highly international, in addition to exhibitors from Hong Kong, the Chinese Mainland and Taiwan, we also welcome exhibitors from Denmark, Finland, Germany, the Netherlands, the United Kingdom and the United States.”Centred on innovation and smart design, the Hall of Connected Lighting, which was upgraded last year, returns as the event’s focal point. The hall features some 70 leading brands, with an increase in the number of brands, countries and regions represented. In addition to showcasing a wide range of innovative smart lighting products and solutions, the hall also features several specially designed experience zones, showcasing meticulously designed scenarios, cutting-edge applications, and technologies. In the experience zone, visitors will be immersed in a multi-dimensional light installation that fuses art and technology, and experience a hands-on encounter with AI integrated applications in health and wellness, as well as innovative solutions for the silver market. The Hall of Connected Lighting features renowned brands such as Casambi from Finland, Moorgen from Germany, Signify from the Netherlands, and Koizumi from Japan, showcasing award-winning designs, designer collections, and lamps and lighting solutions used in iconic projects around the world. Major industry alliances playing key roles in the fields of smart lighting and the Internet of Things are gathered at the fair, including the DALI Alliance and SILA-EMN Alliance, as well as new participants this year such as the Connectivity Standards Alliance and the Zhaga Consortium, collectively presenting the full spectrum of the smart lighting ecosystem. They bring together member enterprises from around the world, including Elite Intelligence, Broadlink and Inventronics from the Chinese Mainland, LEDiL from Finland, France’s Nicolaudie, and Germany’s CUPOWER to showcase the smart lighting ecosystem.Another highlight is the Hall of Aurora, which brings together some 540 renowned brands offering high-quality lighting products. They include Prosperity Group and General Lighting from Hong Kong, LEEDARSON, Tospo and Je Woo from the Chinese Mainland, Lival from Finland and Megaman from Germany. Other featured zones include Commercial Lighting, LED Essentials, LED Lighting, Residential Lighting and Testing, Certification & Inspection, providing buyers with one-stop sourcing opportunities.The Hong Kong International Outdoor and Tech Light Expo showcases a diverse range of outdoor commercial and industrial lighting solutions, enabling the development of smart cities. The Smart Pole and Solution Zone, introduced last year, will return to showcase innovative solutions that aid in enhancing the quality of life and energy efficiency optimisation. E-Lite Semiconductor Inc. showcases its smart light poles, equipped with energy-efficient LED lighting and Environmental Sensing technology. These poles monitor air quality, temperature, humidity, and noise levels, and assist with real-time traffic monitoring when integrated with traffic cameras and sensors. Furthermore, Shenzhen Zhongchuang Lighting Technology presents its patented modular square stadium lights in the Technical & Professional Lighting zone. Engineered for functionality, the product allows for individual module replacement in the event of damage – greatly simplifying installation and maintenance while reducing operational costs. The Horticultural Lighting zone showcases advanced horticultural lighting technologies and multifunctional lamps suitable for outdoor parks and home gardens. The Outdoor and Public Lighting zone continues to showcase lamps designed for outdoor public spaces and advertising.Twin fairs focus on multiple lighting trendsImmersive smart lighting experience and design master series Smart homes are becoming increasingly popular. According to Statista, smart lighting is projected to become a massive $44 billion market by 2030, allowing users to adjust brightness, colour and temperature as needed. Exhibitors at this year's Autumn Lighting Fair have also thoughtfully designed various settings to offer buyers hands-on experiences. For example, Casambi has created the Artisan Café, a boutique coffee space illuminated in collaboration with ERCO, a globally acclaimed architectural and commercial lighting brand. Combining digital lighting systems with on-site ambiance, the café offers attendees a unique and immersive experience to connect and exchange ideas while enjoying their coffee. The lighting is configured to simulate natural light at different times of the day, featuring four distinct scenario demonstrations. TUYA Smart has constructed scenes such as living room and a bedroom to demonstrate how lighting and AI technologies can be integrated into smart lighting solutions. Moorgen also presents several cross-over collections from global design masters, including smart lamps designed in collaboration with two receivers of the DFA World’s Outstanding Chinese Designer Award, Chi-wing Lo and Tino Kwan; acclaimed Hong Kong architect, interior and product designer Steve Leung; Spanish designer Jorge Herrera; and internationally renowned design studio Yabu Pushelberg. Among the innovations on show, the Flower of Paris Motorised Track Light makes its global debut at the Autumn Lighting Fair and features a design collaboration with Ma Yansong – the first architect from the Chinese Mainland to win the right to design an international landmark building. As the result of two years’ development, the track light features a 355-degree rotating head and adjustable beam angles of 10, 15 and 25 degrees, flexibly illuminating every detail. Equipped with an intelligent control system, the track light can be operated remotely with effortless scene switches. Architectural lighting fixtures designed by Tino Kwan also makes a Hong Kong debut.Lighting and health are interdependent "Human-centric lighting" will continue to be a key focus in 2025. From lighting solutions that align with circadian rhythms to antibacterial UV-C technology, lighting is becoming a tool for enhancing health. Signify unveils its VitaUp Vitamin D3 Modules by Philips at the fair, offering a safe, controlled source of low-intensity UVB exposure to naturally support healthy vitamin D levels. Designed for long-term and low-intensity use, five-days of exposure delivers the equivalent UVB dose of a 15-minute midday walk two to three times per week in spring or summer. Another highlight is that Jiangsu Insona Communication Technology Co. also brings a smart lighting system that uses a circadian algorithm synchronised with local sunrise and sunset times without requiring network connectivity, thereby supporting the body’s natural biological rhythm. Foshan Electrical and Lighting Co. also sets up an experience zone to launch its Eye-care Ceiling Light, specially designed to meet the needs of the silver market. Tailored for elderly people, the light improves visual clarity by 15%, supports circadian rhythm and boosts lighting efficiency by 12%, reducing eye fatigue.Award-winning designs and global landmark lighting showcased at the twin fairs According to a lighting industry survey conducted by the HKTDC in April, 37% of respondents believe LED lighting has the greatest growth potential. A wide array of LED-innovations are on display, including the Filmbase flying screen developed by Filmbase Tech, a national-level high-tech and Specialised, Refined, Distinctive and Innovative enterprise. This ground-breaking product has set a new Guinness World Record as the world’s largest LED mesh mid-air suspended screen. Hong Kong’s GRE Alpha brings LED drivers and light strings that were used in the lighting show and horticultural system at Gardens by the Bay in Singapore. General Lighting Innovation showcases its Neon Strip which is renowned for its exceptional flexibility, impact resistance and all-weather durability. The latest models allow custom cutting and instant connection on site, enabling versatile installation to suit various spatial designs and creative lighting applications. At the Hong Kong International Outdoor and Tech Light Expo, AGC Lighting Co showcases several outdoor lighting fixtures that have won the German IF Design Award and the Red Dot Design Concept Award. Among them, the UFO High Bay Light features a unique design, enhanced by precision optics and high-efficiency power components. Its integrated system allows for both power and correlated colour temperature (CCT) adjustments in the one fixture.Experts discuss market trendsThe Innovative Lighting Design Forum held today (27 October) at the HKCEC explored two key themes: “City Design.Design City: Lighting Design Bound Up with Daily Life” and “RCEP Opportunities Shining Through Cultural Lighting Design”. Speakers included representatives from celebrated international and local companies, as well as architects and lighting designers, who shared top design cases from various regions and analysed market trends. Tomorrow (28 October), the Connected Lighting Forum will delve into smart living ecosystems and sustainable lighting development. It will also feature the launch ceremony for “Edge Mixed Networking (EMN) Technical Requirements for Smart Buildings”. On the same afternoon, renowned lighting designer Tino Kwan will host a masterclass titled “The Language of Light: From Artistic Design to Everyday Experience” and share design principles for enhancing daily life through light and the impact of light on mood, functionality and spatial characteristics. Additionally, a seminar titled “Illuminating the Cycle: Outdoor Lighting Designs for a Sustainable Future” will be held tomorrow (28 October) at AsiaWorld-Expo, focusing on how outdoor lighting can integrate sustainability concepts.Running concurrently from 28 to 31 October, the Outdoor and Tech Light Expo and Eco Expo Asia at AsiaWorld-Expo, alongside the Autumn Lighting Fair at the Hong Kong Convention and Exhibition Centre (HKCEC), present a dynamic platform for cross-sector business opportunities. Free shuttle bus services will be provided between the HKCEC and AsiaWorld-Expo from 28 to 30 October.Under the EXHIBITION+ hybrid model, exhibitors and buyers can meet online through the Click2Match business matching platform in addition to attending the physical fair. The online fairs run from 20 October to 7 November, facilitating business expansion both online and offline. 27th HKTDC Hong Kong International Lighting Fair (Autumn Edition)10th HKTDC Hong Kong International Outdoor and Tech Light ExpoDate27-30 Oct 2025 (Monday to Thursday)28-31 Oct 2025 (Tuesday to Friday)Opening hours27-29 Oct 2025: 9:30am-7pm30 Oct 2025: 9:30am-4pm28 Oct 2025: 10:30am-6pm29-30 Oct 2025: 10am-6pm31 Oct 2025: 10am-5pmVenueHong Kong Convention and Exhibition CentreAsiaWorld-ExpoPress Registration CounterHall 1C Concourse, HKCEC, or at the HKTDC Media Centre (G/F, HKCEC, 1 Expo Drive, Wan Chai)AsiaWorld-Expo East LobbyMedia CentreHKTDC Media CentreRoom 108, Hall 8 Side Entrance, AsiaWorld-ExpoFair websitehklightingfairae.hktdc.com/tchkotlexpo.hktdc.comPhoto download: http://bit.ly/43F182CThe 27th HKTDC Hong Kong International Lighting Fair (Autumn Edition) opens today, showcasing a wide variety of smart lighting products and solutions.The Hall of Connected Lighting returns, showcasing designs and smart technologies from prominent companies and brands.Under the theme ‘Illuminated Designs for a Smarter Future’, exhibitors at the twin lighting fairs present multiple experiential zones featuring meticulously designed lighting scenes, cutting-edge applications, and technologies, allowing visitors to immerse themselves in a multi-dimensional light and shadow experience at the intersection of art and technology.The Hall of Aurora brings together some 540 notable brands offering high-quality lighting products and technologies.The Innovative Lighting Design Forum took place today and explored two key themes: “City Design.Design City: Lighting Design Bound Up with Daily Life” and “RCEP Opportunities Shining Through Cultural Lighting Design”. Representatives from celebrated international and local companies, as well as architects and lighting designers, shared design works from various regions and analysed market trends.Media enquiriesPlease contact the HKTDC’s Communications & Public Affairs Department:Stanley SoTel: (852) 2584 4049Email: stanley.hp.so@hktdc.orgClayton LauwTel: (852) 2584 4472Email: clayton.y.lauw@hktdc.orgHKTDC Newsroom: http://mediaroom.hktdc.com/enAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SINGAPORE, Oct 27, 2025 - (ACN Newswire via SeaPRwire.com) - Terrapinn announces the 10th anniversary edition of EDUtech Asia, Asia’s largest and most influential education event, taking place on 5 - 6 November 2025 at Sands Expo & Convention Centre, Singapore. Under the theme “Positive disruption: unlocking limitless potential in education with AI and tech,” the event will bring together more than 8,000 education leaders, policymakers and technology innovators to explore how AI is transforming learning while ensuring that human connection, purpose and equity remain at the heart of education.Global Visionaries Lead the AI ConversationThis year’s keynote lineup features some of the most influential voices in global education. Professor Pasi Sahlberg(University of Melbourne) will examine why many schools remain “tech-rich but transformation-poor” and what must change to unlock AI’s true impact on learning and equity. Dr Yuhyun Park, creator of the Digital Intelligence (DQ) Framework, will reveal how education systems can rapidly build AI literacy and empower every learner to thrive in an AI-driven world. Graham Brown-Martin, renowned futurist and Founder of Learning Without Frontiers, will explore how AI, immersive technologies and human skills are converging to shape a new global learning ecosystem. A major highlight will be the live keynote debate featuring Professor Pasi Sahlberg and Associate Professor Dr Ng Pak Tee (National Institute of Education, Singapore), who will confront one of the most important questions facing global education: Can AI ever replicate the human heart of teaching, or is the future of learning defined by a powerful partnership between human and machine intelligence?A Conference Designed for Actionable ImpactThe conference will feature 350+ speakers across five stages, presenting case studies and panel discussions on AI adoption, assessment redesign, future skills, institutional transformation and digital leadership. Delegates will participate in interactive roundtables and hear real-world strategies from schools and universities across Asia. The EDUtech Asia Awards will celebrate excellence in AI innovation, sustainability, STEAM education and industry collaboration.“EDUtech Asia has always been about driving real change through collaboration and innovation,” said Sophia Ku, Managing Director, EDUtech Asia. “As we celebrate this milestone year, the 2025 edition will be our most significant yet. We’re not just responding to change, but actively leading it. We are bringing together the educators and innovators who are shaping the AI-driven future of learning across Asia, providing them with the knowledge, inspiration and partnerships to unlock the full potential of technology in education.”Asia’s Largest Education Technology ExhibitionRunning alongside the conference, the exhibition will feature over 200 EdTech providers including Google for Education, Lenovo, Samsung, Canvas by Instructure, EdX, AWS and Jamf. Attendees will experience new AI tools and digital platforms through live demonstrations and Start-Up City showcase. The Show & Tell sessions will allow educators to share real classroom case studies and digital transformation success stories. Meanwhile, the 2nd annual Planet Protectors Sustainability Challenge, in partnership with Google for Education, will highlight student-led initiatives tackling environmental issues through innovation and technology.Registration Now OpenPremium conference passes and free exhibition visitor passes are available at: www.terrapinn.com/JoinEDUtechAsia2025ACNEvent Details: EDUtech Asia 20255–6 November 2025Sands Expo & Convention Centre, SingaporeFor more information on EDUtech Asia 2025, please visit: www.terrapinn.com/JoinEDUtechAsia2025ACNAbout Terrapinn Terrapinn has been sparking ideas, innovations and relationships that transform business for over 30 years. Using our global footprint, we bring innovators, disrupters and change agents together, discussing and demonstrating the technology, strategies and personalities that are changing the way the world does business. Whether you’re looking to make new connections, introduce product or inspire change in your industry, we invite you to join us as agitators of change. Terrapinn – spark something For more information, visit www.terrapinn.com.Press attendance is complimentary. Enquiries should be directed to: Jessica Foong at jessica.foong@terrapinn.com Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com